VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
| 1.9 | |
| 1.77 | |
| - | |
| 1.92 | |
| 1.77 | |
| 1.57-4.4808 | |
| 28 024 K | |
| 1.1047 | |
| 14 749 K | |
| 486 K | |
| -0.22 | |
| 1.456 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
In this article, we will be taking a look at the 15 best acne treatment products for teens in 2024. If you are not interested in reading about the teen tailored skin innovations in detail, head straig...
Transformative capital raise of $88.2 million from leading healthcare investors provides funding for BET inhibitor programs through the end of 2025 Phase 2b preparatory activities progressing for VYN...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
